INSEMPRA
25.5.2023 08:01:30 CEST | Business Wire | Press release
Insempra, a biology-powered company enabling businesses to make superior products with nature, and Fibers365, a company offering chemical-free processed fibers and substrates from annual plants, today announce that they are working together to develop and scale sustainable second-generation (2G) feedstock for the commercial production of fermentation-based ingredients.
2G feedstocks, also known as lignocellulosic feedstocks, are a key area of research and development in biotechnology as the industry is facing a growing need in the application of these in fermentation processes. Fast moving consumer good companies, for example, are demanding sustainably procured raw materials. By utilizing agricultural residues, 2G feedstock has the potential to reduce greenhouse gas emissions by replacing fossil-based and de-forestation-based ingredients and consumer products. Insempra has built a broad toolbox to use feedstocks derived from agricultural wastes and also upcoming intermediates originating from carbon capture methods.
The Fibers365 patented, modular, farm level Steam Fiber Plants allow the competitive extraction of functional cellulosic fibers, lignin and sugars from multi feedstock non-wood biomass. The sugars, currently used for the generation of biogas, can be further valorized by producing high-value products via fermentation for various industrial applications.
“By working together with Insempra, we are combining our unique 2G feedstock derived from agricultural side streams with the highly advanced fermentation technology platform needed to scale and make this sustainable feedstock accessible to broader applications.” said Stefan Radlmayr, Founder and Managing Partner of Fibers365.
One of the primary challenges with 2G feedstocks is the intrinsic material stability of lignocellulosic materials. Unlike first-generation feedstocks (e.g., those derived from beets, corn, sugarcane), which contain easily accessible sugars, lignocellulosic biomass is composed of complex structures that require pre-treatment and enzymatic hydrolysis to release the sugars. Developing efficient and cost-effective pre-treatment methods and robust enzymatic cocktails for biomass deconstruction is a key challenge in the adoption of 2G feedstocks at scale.
Insempra has successfully tested Fibers365’s 2G feedstock derived from agricultural waste streams (e.g., wheat straw) with its proprietary fermentation technology platform. Insempra is using this technology for the development of speciality lipids for application in the beauty and personal care as well as nutraceuticals and food industries. In addition to speciality lipids, Insempra is also working on the production of protein fibers and high-value functional ingredients with 2G feedstocks from agricultural waste.
“Using second-generation feedstocks in our manufacturing processes has always been one of our priorities as a biology-powered business. We are tremendously excited about the potential this technology not only has for our businesses, but for the whole industry.” said Jens Klein, CEO & Founder of Insempra.
By working together, Insempra and Fibers365 tackle the challenge of scaling and aim to maximize the potential of 2G feedstocks to support their mission to manufacture at scale in collaboration with nature, thereby contributing to a more sustainable and circular future.
About Insempra
Insempra GmbH, Munich (Germany), is a biology-powered company enabling businesses to make superior products with nature. We combine bioscience and technology to grow matter for new and better products.
For too long, businesses have relied on chemical industrialization processes and petrochemicals, depleting our planet’s limited resources. That’s why we are committed to drive the regenerative revolution to manufacture at scale in collaboration with nature.
Led by a hand-picked team of biologists, technologists, and entrepreneurs with rebel hearts, Insempra is here to create a new school of thought and collective action. The time to restore the balance between people and the planet is now. We don't wait for change. We do what needs to be done to grow a better future.
Learn more about Insempra at insempra.bio
About Fibers365
Fibers365 GmbH, Lenningen (Germany), offers a unique, multi-feedstock biomass processing technology for annual plants to provide functional, competitive non wood biomass products such as virgin fibers for paper, packaging and textile applications as well as high value biopolymer and fertilizer side streams, produced with carbon neutral bioenergy. The products are extracted from agricultural residues such as straw by a chemical-free, regional, farm level steam explosion pulping technology, allowing easy separation of cellulosic fibers from sugars, lignin, organic acid and minerals. The use of annually regrown plants allows to compensate CO2 emissions from processing and product consumption almost instantly, by closing a yearly carbon loop.
Learn more about Fibers365 at fibers365.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005793/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer27.10.2026 08:30:00 CET | Press release
Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 First EU approval of Enhertu in the curative-intent early breast cancer setting Third approval for Enhertu in the EU in four months Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for
Avanzanite Bioscience Expands UK Presence and Appoints Sarah O’Connell as Country Manager27.10.2026 08:00:00 CET | Press release
Avanzanite Bioscience B.V., a European pharmaceutical company focused on rare diseases, today announced the expansion of its United Kingdom (UK) presence and the appointment of Sarah O’Connell as UK Country Manager. The move strengthens Avanzanite’s long-term commitment to the UK and its ability to help eligible patients access innovative rare disease medicines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027035012/en/ Sarah O'Connell, Country Manager, UK, Avanzanite Bioscience “The UK is essential to our ambition of building Avanzanite into a European rare disease champion. We feel a deep and lasting connection to this market and there is no European reach without the UK,” said Adam Plich, co-founder and CEO, Avanzanite Bioscience. “At a time when parts of the life sciences sector are reassessing their investment and presence in the UK, we are choosing to commit and build for the long term. With Sarah’s extensive rare
LTM Secures Strategic Engagement with a Global Banking and Financial Services Firm27.10.2026 05:30:00 CET | Press release
LTM, the Business Creativity partner to the world's largest enterprises, has secured a strategic engagement with a large global banking and financial services firm, further strengthening its position as a trusted technology and transformation partner to leading financial institutions. This two-year engagement is already underway with an option to extend for an additional year and has a potential value of up to USD 100 million. The engagement reflects the continued expansion of LTM’s relationship with the client and its growing role in advancing strategic technology programmes and supporting supplier consolidation initiatives across the organization. Under the agreement, LTM will serve as a preferred partner driving the consolidation and delivery of strategic technology requirements across key wealth, personal banking, and global functions. The engagement will leverage LTM’s deep banking-domain expertise, engineering excellence, and global delivery capabilities to support the client’s t
DDN Selected to Modernize Research Data Infrastructure at UNSW Sydney26.10.2026 22:30:00 CET | Press release
DDN EXAScaler and Arcitecta Mediaflux will replace 11 legacy storage systems, simplifying access to research data while balancing performance and cost DDN, the global leader in AI and data intelligence solutions, today announced that UNSW Sydney has selected DDN to deliver a new research data storage environment as part of the university’s Research Data Experience (RDE) program. Working with Australian software company Arcitecta, DDN will combine its EXAScaler parallel file system with Arcitecta’s Mediaflux® data management platform to help researchers spend less time managing data and more time using it. Following an extensive 18-month evaluation, UNSW selected an integrated approach that will replace 11 legacy storage systems with a coordinated environment for high-performance storage and enterprise data management. The decision reflects a broader challenge facing research-intensive institutions: how to support rapidly expanding scientific datasets while simplifying infrastructure, i
Agent Assurance by TestMu AI Is Now Generally Available, Letting Teams Test What Their AI Agents Actually Change26.10.2026 16:15:00 CET | Press release
The trial includes 4,000 credits and four concurrent runs, so a team can generate functional and adversarial suites from its own agent's docs and endpoint, with code optional, and gate CI on evidence-backed verdicts without booking a demo. TestMu AI (formerly LambdaTest), the world's first Agentic AI-powered Quality Engineering platform, today announced the general availability of Agent Assurance. Agent Assurance tests AI agents that take actions, such as calling tools, writing files, and changing records, by checking what a run actually changed rather than what the agent says it did. Any team can now create a TestMu AI account and run it against its own agent without booking a demo first. Agent Assurance launched on August 17, 2026, behind a waitlist and a guided onboarding session. Since then, Rook, the CLI that runs Agent Assurance, has shipped a steady run of releases, shaped by feedback from early teams. Agent evaluation has mostly graded the final reply, and that reply can be wro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom